Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0092 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2021-06-29^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a35f4f387afb5d71d0027e4583ecd39b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28b7adc7c68036a0042639eb949c50bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0adc3ecc1d540bc8d9a270469529f201 |
publicationDate |
2022-01-06^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2022006083-A1 |
titleOfInvention |
Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic |
abstract |
In various embodiments nanoparticle drug delivery vehicles are provided herein for the effective delivery of a GSK3 inhibitor. In certain embodiments the drug delivery vehicle comprises a nanoparticle comprising one or more cavities disposed within the nanoparticle and an outside surface where the one or more cavities are in fluid communication the outside surface of the nanoparticle; a GSK3 inhibitor disposed within said one or more cavities; and a lipid bilayer disposed on the surface of said nanoparticle where said lipid bilayer fully encapsulates said nanoparticle. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114870035-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114870035-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115212321-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023060226-A1 |
priorityDate |
2020-06-30^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |